Insights Into Hepatocellular Carcinoma (HCC)

Perspectives on drivers in treatment decisions in the management of HCC

Northeast – April 18, 2023

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ, USA

Southeast – June 22, 2023

Faculty Chair

Daniel Ahn, DO

Mayo Clinic Cancer Center, Phoenix, AZ, USA

Central – July 12, 2023

Faculty Chair

Tanios Bekaii-Saab, MD

Mayo Clinic Cancer Center, Phoenix, AZ, USA

West – October 10, 2023

Faculty Chair

Daniel Ahn, DO

Mayo Clinic Cancer Center, Phoenix, AZ, USA

More Information

  • Virtual program
  • Connecticut, Delaware, District of Columbia, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • West

Example Agenda

Download the meeting agenda

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the treatment of HCC
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained: sorafenib vs lenvatinib; checkpoint inhibitors including atezolizumab and nivolumab; cabozantinib, nivolumab vs pembrolizumab, ramucirumab (high alpha-fetoprotein [AFP]), regorafenib, ipilimumab + nivolumab

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.